Hey daddy, take a look at this chart;
Everything has been amazing so far, we just need the CV event rate to meet the FDA's demands. It sounds funny to say that there has not been enough CV events to satisfy the FDA. There is some evidence suggesting that the higher rate of testosterone vs estrogen is something that protects females from CV events as they age. Could you imagine if this became medical fact )) wooo hoooo horny and hreat healthy
They would not hold back data for this event unless it was steller, so we should hear some good news. stock should keep running into the conference.
I lived in asia for a while, women use this stuff like crazy. and that is the much less effective stuff.
Testosterone treatment in women has been used off-label by ob-gyn doctors since the 1990's. Efficacy has already been proven--the FDA knows this-----they are worried about safety and side-effects to approve any drug like Libigel.
Biosante is all over safety with their clinical trials and next's week report from Biosante is critical will hopefully put this unmet treatment area for women to bed for the FDA.